Category: clinicial practice
The Use of Cell-free DNA in Clinical Practice: Work in Progress
A recent review outlines the use of circulating tumor DNA (ctDNA) in clinical practice and the requirements necessary to extend the use of this technology for health impact. Cell-free DNA (cfDNA) is extracellular strands of DNA present in body fluids. Circulating tumor DNA (ctDNA) is a specific type of cfDNA that originates from a primary tumor, circulating Read More >Posted on by Leave a comment
Polygenic Risk Scores in Clinical Practice? Still Making the Case
Two recent systematic reviews show the lack of data on clinical utility of polygenic risk scores and major challenges in implementation. The Promise of Polygenic Risk Scores in Population Health Many common diseases such as cancer, diabetes, and heart disease, result from the combination of genetic factors and physical and social environmental factors. Genome-wide association Read More >Posted on by Leave a comment
Is it Time to Integrate Polygenic Risk Scores into Clinical Practice? Let’s Do the Science First and Follow the Evidence Wherever it Takes Us!
In case you have not been paying much attention to genomic medicine research or social media coverage, you might have missed a clear uptick in the past couple of years on the value of polygenic risk scores in clinical practice and population screening. (see examples here, here, here, and here) Polygenic risk scores (PRS) summarize Read More >Posted on by 1 Comment